Onglyza advisory panel review
Bristol-Myers Squibb/AstraZeneca's DPP-4 inhibitor Onglyza (saxagliptin) will be reviewed by FDA's Endocrinologic and Metabolic Drugs Advisory Committee April 1. The application was filed last summer and an action date is set for April 30 (1"The Pink Sheet" DAILY, July 23, 2008). Novo Nordisk's GLP-1 analog Victoza (liraglutide) already was on the committee calendar for April 2, an event that has been anticipated as the showcase for real-world implementation of new cardiovascular safety guidance governing type 2 diabetes drugs. Unveiled in December, that guidance requires an in-depth safety review for type 2 diabetes medications, including studies of CV mortality, myocardial infarction and stroke (2"The Pink Sheet" DAILY, Dec. 17, 2008)
You may also be interested in...
In raising pre-market safety standards, FDA says that development time will not necessarily increase if a robust protocol is used.
Scrutiny of potential cardiovascular risks looms over new diabetes drugs.
The European Directorate for the Quality of Medicines & HealthCare is proceeding carefully to find the right balance between serving the diverse requirements of various stakeholders that make use of its ‘certificates of suitability.’